An introduction to methicillin resistant S. aureus (MRSA), the challenge of antibiotic resistance and the recent epidemiological change in Europe. An overview of some of the key risk factors related to MRSA infection and the impact that these infections have on mortality rates.
Key identifiers of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) and the burden of these conditions in European healthcare facilities. S. aureus in the context of HAP.
A brief review of vancomycin and linezolid, discussing potential limitations and potential factors to consider when selecting treatment. A summary of the importance of rapid and considered treatment choice in the context of patient mortality.
The structure of telavancin, with focus on its difference with vancomycin – a traditional glycopeptide – highlighting the potential functional benefits of these modifications.
A synopsis of telavancin’s unique mode of action, including its ability to inhibit bacterial cell wall synthesis and disrupt bacterial cell membrane functionality.
LA summary of the efficacy of telavancin against MRSA and MSSA (methicillin susceptible S. aureus), including efficacy data relating to head to head comparisons with vancomycin and linezolid in defined areas.
A summary of the efficacy of telavancin in a wide range of animal models, including head to head comparisons with vancomycin and linezolid.
An overview of the pharmacokinetics of telavancin, including evidence to support a once-daily IV dosing regime.
A summary of the clinical outcomes established in the phase III ATTAIN studies, including a post-hoc analysis excluding patients with renal impairment.
The safety and tolerability profile of telavancin, including an overview of renal toxicity and recommendations regarding dose adjustments in this context.